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The pre-Socratic philosophers were reputed to be
able to entertain two mutually contradictory beliefs
with apparent equanimity. In reading this review,
which undoubtedly reflects the bias of the writer and,
in turn, the authors of the cited works, the complexi-
ty and contradictory nature of much of the data will
be evident; one cannot view, however, the result
with any degree of equanimity. Much remains to be
done in the experimental field before a unifying con-
cept on the pathogenesis, incidence, and implica-
tions of analgesic nephropathy can be enunciated.
Scope of the problem. The review of Gsell [11
"From phenacetin nephritis to analgesic nephropa-
thy" admirably reflects the change in attitude to the
problem, particularly in the last ten years. Since
other investigators have indicated the current scope
of the problem [2—22], no further comment is need-
ed. Adverse reactions referable to the kidney are
attributed to aspirin (used alone and in combination
with other agents), phenacetin (in combination), par-
acetamol (alone and in combination), phenylbuta-
zone, oxyphenbutazone, ketophenbutazone, sul-
phinpyrazone, indomethacin, ibuprofen, ketoprofen,
fenoprofen, tolmetin, glaphenine, niflumic acid,
mefanamic acid, tolfenamic acid, bucloxic acid, ado-
fenac, and naproxen. The data used in this review
are derived both from published reports and drug-
monitoring committees (Table 1) [23—66]. In sum-
mary, salicylates and phenacetin used in combination
and aspirin used alone are frequently implicated, the
pyrazoles less so; and the newer nonsteroidal antiin-
flammatory agents, e.g., the phenylalkanoic acids
and fenamic acids, play a small but significant part.
Occasional reports implicating dextropropoxyphene,
caffeine, and older analgesics are also noted.
Pharmacological and toxicological studies in animals and
man
Short-term therapy. Indomethacin administration
(150 mg/day, for three days) was shown to induce
water and sodium retention both in normal subjects
and in patients with kidney damage [73—75]. In
15
patients with preexisting reduction in glomerular fil-
tration rate (GFR) and renal plasma flow (RPF), this
reduction was intensified, and sodium restriction led
to a more pronounced effect; normal subjects
showed no change in GFR or RPF. In another study,
indomethacin administration (150 mg/day) decreased
the GFR by 35% and the RPF by 23% in nephrotic
patients with impaired renal function.
Both phenylbutazone and ketophenbutazone
administrations (single dose of 600 mg, either orally
or i.m.) were shown to impair '311-hippuran excre-
tion, which was interpreted as an acute impairment
of tubular function [76]. In another study [77], the
isotope renogram was used to measure the changes
induced by oxyphenbutazone administration (750 mg
daily). These changes were interpreted as a reflection
of impaired blood flow, tubular function, and there-
fore, clearance of the isotope.
In normal subjects, the short-term administration
of aspirin (oral doses of 5.5 g daily) was shown to
produce sodium retention, a decreased urine vol-
ume, and tubular reasorption of free water; no
change in creatinine clearance was noted. The effect
was more pronounced when plasma renin had been
elevated by low sodium balance [73, 74]. In patients
with chronic renal insufficiency, aspirin i.v. (lysine
conjugate, 750 mg) caused a decrease in sodium renal
excretion within 15 mm which lasted for six hours, a
decrease in GFR to 54%, and a decrease in RPF to
66% of control values [73].
Aspirin was shown to reduce the glomerular filtra-
tion rate in 13 patients with renal impairment by 10%
when given 20 mg/kg by mouth, while in a further
eight subjects [78], with no renal impairment, the
lysine conjugate of aspirin (0.9 g, i.v.) produced a
significant reduction in GFR and PAH clearance in
seven [79]. The effect was transient, however. The
blood salicylate concentration at the time of maximal
effect was 12.4 mg/l00 ml. The effect of aspirin in
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Table 1. Data for agents which have been correlated with adverse reactions reibrable to the kidneya
Phen- Para- Phenyl- Oxyphen- Indo- Keto- Mefanamic Flufenamic
Aspirinc acetin" cetamol' butazone' butazone methacin5 Ibuprofenh profen' acid' acid Aclofenac5 Naproxen
Abnormal urine 1 2 2
Acute renal failure 3(2) 5(4) 2 2
Abnormal function 1 2 1
Abnormal and
deteriorating function 3(2) 2(1) 1(1) 1(1)
Renal papillary necrosis 27(16) 52(40) 6(4) 4(2) 1(2) 3(2) 2(1)
Tubular necrosis 2(1) 2(1)
Hematuria 4 7 5 6 I 2
Interstitial nephritis 1
Glomerular nephritis 1
Albuminuria 1 1 1 1
Toxic nephropathy 5(1)
Nephrosis 2 1
Dysuria/oliguria Ill
Data provided by the Committee on Safety of Medicines [23] for period March, 1964, to December1975, except as follows: ibuprofen, 12/65—12/75;
ketoprofen, 2/70—12/75; flufenamic acid, 6/67—12/75; aclofenac, 4/70—12/75; naproxen, 7/70—12/75.
Figures in brackets denote fatal outcome.
For data on fenoprofen, see [44]; tolmetin, see [45]; glaphenine, see [50-60]; niflumic acid, see [61-63]; bucloxic acid, see [64, 65]
See also [4, 24, 25].
See also [26-29].
See also [30].
See also [22, 31-35].
See also [36-38].
See also [39, 40].
See also [41-43].
See also [66].
See also [46, 47].
'See also [38, 48, 49].
Bucloxic acid: See also [64, 65].
reducing the urinary excretion of xylose is probably
due to its reduction of GFR [801. Ingestion of aspirin
causes a transient shedding of renal tubular cells into
the urine; excretion of enzymes, however, e.g., lac-
tate dehydrogenase (LDH) and N-acetyl-/3-D-glu-
cosaminidase (NAG), persists. NAG excretion is a
sensitive test of renal damage and correlates well
with impairment of concentrating power and experi-
mental papillary necrosis in dogs [81, 82]. Leath-
wood and Plummer [83] gave 3 g of aspirin acutely to
normal subjects, and Burry et al [81, 821 adminis-
tered 4 g of aspirin to both normal subjects and
patients with rheumatoid arthritis. Leathwood and
Plummer produced persuasive evidence that the kid-
ney is the main source of LDH and that both celluria
and rise of LDH levels indicate cell damage. Burry
found that NAG levels were elevated ten days after
dosing, all values being higher in patients than in
healthy subjects, indicating persisting tubular dam-
age which, however, is considered to reflect a mini-
mal impairment of tubular function.
Long term therapy. Retrospective studies of renal
function in patients who have received salicylate for
long periods have been contradictory. Burry et al
[81, 821 suggested that when a large amount of sali-
cylate is consumed over many years, an appreciable
degree of tubular function impairment results.
Dieppe et a! [84] found, however, that in 8 of 20
patients with rheumatoid arthritis who had received
no drug treatment, the NAG excretion was abnor-
mally high, so that rheumatoid arthritis per se may
be important. Salant [85] found that in patients with
analgesic nephropathy (drugs not stated), distal tubu-
lar function was impaired out of all proportion to the
degree of reduction in the glomerular filtration rate.
The conflicting and inconclusive data from renal
lunction studies in rheumatoid arthritis has been
reviewed by Nanra and Kincaid-Smith [9].
The New Zealand Rheumatoid Association study
[86] exonerated aspirin as a cause of nephrotoxicity
on the basis of "a renal score" and creatinine clear-
ance tests, but no measurement of tubular function
was made. In contrast to the findings of Edwards et
a! [871. Burry [81] detected no relation between
glomerular function (creatinine clearance) and the
dose of aspirin consumed; endogenous creatinine
clearance, however, although inappropriate as a test
of renal tubular function, should not be interpreted
as an index of GFR when salicylates are adminis-
tered [881. The salicylate itself probably disturbs the
protein binding of creatinine or affects its tubular
secretion. The renal clearance of Cr-edetic acid
was normal in subjects who showed a reduction in
creatinine clearance; so the test is not suitable in
assessing renal function in patients receiving
salicylate.
In sharp contrast to the findings of Berg [73, 741,
Elliot and Murdaugh [891, and others, patients with
analgesic nephropathy (compound analgesics), i.e.,
where drugs have been administered chronically,
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show significant sodium loss (i.e., the urinary sodium
is inappropriately high). Such depletion will, in turn,
impair renal function, and this would correlate with
the known loss of long nephrons, as the remaining
short nephrons have a lower capacity for sodium
absorption [901.
Patients with analgesic nephropathy may suffer
from diminished concentrating ability, and this is
most clearly shown when compound mixtures have
been taken for long periods; the evidence implicating
aspirin has been briefly summarized above. Much
less data is available with regard to paracetamol;
but in a thorough study, Edwards et al [911 found
no evidence of impaired function (including concen-
trating power) in 18 patients with rheumatoid arthritis
who had consumed between 2 to 30kg of paracetamol
in the past and at least one gram of paracetamol daily
per year prior to the examination.
Aspirin is under investigation in the secondary
prevention of myocardial infarction, and the most
detailed study published to date is that of the Coro-
nary Drug Project [921. Seven hundred and twenty-
seven patients received one gram of aspirin daily for
10 to 28 months. "Blood in urine" was reported in
1.2%, compared to 0.3% of 744 patients receiving
placebo. This was not, however, confirmed by dip-
stick measurement of hematuria (1.53% of 523
patients receiving aspirin, compared with 2.08% of
528 patients receiving placebo). Urine protein, how-
ever, was higher in the aspirin group.
In a prospective study, Dubach, Rosner, and MUll-
er [27] showed that concentrating power was signifi-
cantly reduced and serum creatinine increased in
high analgesic users. Bengston [93], however, con-
sidered that the incidence of lesions in the study was
underestimated, and it is difficult to reconcile the
conclusions of the paper with the findings therein.
Pharmacological and toxicological studies in animals
Any pharmacological analysis must take account
of the relevance of the species employed, the doses
used, whether a dose-response curve is demonstra-
ble, and finally, the experimental conditions under
which the studies were conducted and how the
results have been interpreted.
Doses employed and relevant pharmacokinetics.
Many studies have employed doses far outside the
realm of pharmacology; In many cases we are deal-
ing with toxicologic studies in the proper sense of the
term. With the wealth of data available, no clear-cut
picture emerges, apart from the fact that very high
doses of agents are required before any lesion is
observed in a consistent fashion.
By comparing the whole-body total salicylate con-
centration in man and Charles Rivers rats, Philips,
Leeling, and Kowalski [441 calculated that single
doses of 24 and 60 mg/kg of body wt in the rat
produced whole-body total salicylate concentrations
that were equivalent to the ingestion of 8 or 20 tablets
(325 mg) of plain aspirin in man. No distinction
between parent and metabolite was made, however,
and the general status of the rats was not reported.
At this dose no lesions were seen, which parallels the
findings of Bokelman et al [94] in rats (with buffered
aspirin) and Mclver and Hobbs [95] in pigs given 1 g/
kg daily for ten months. Nanra [71, 72], however,
with intermediate dose levels of aspirin (200 mg/kg!
day) given from 10 to 60 weeks under conditions of
dehydration, produced renal papillary necrosis in 7
of 13 rats, and 5 showed changes typical of chronic
interstitial nephritis. No control group with free
access to fluid was included, however. High doses of
aspirin or APC have produced renal papillary
necrosis consistently (Nanra, Kincaid-Smith [70, 96,
97]: 500 mg/kg aspirin, 900 mg/kg APC; Saker and
Kincaid-Smith [134]: 500 mg/kg/day phenacetin, 500
mg/kg/day APC). The latter dose of APC is equiva-
lent on a wt/wt basis to that taken by some patients,
but it is excessive on the basis of calculations of
Philips et al [44]. It should be noted enpassant that
the general health of rats given aspirin or APC at this
dose level was "dreadful" (Nanra [71]).
In other studies, large doses of indomethacin (75
mg/kg/day) and phenylbutazone (400 mg/kg/day) giv-
en to female Wistar rats produced renal papillary
necrosis, while smaller doses of indomethacin (4 mg/
kg) produced changes in the basement membrane of
the glomerulus [98]. Phenylbutazone, when given
therapeutically to a dog at a dosage of 25 mg/kg,
induced tubular damage [99]; 40 mg/kg given for 21
days in the cat produced tubular necrosis. Enormous
doses (3,000 mg/kg/day) of phenacetin [100] were
required to produce even modest tubular damage,
while 3,000 mg/kg/day of paracetamol (Nanra and
Kincaid-Smith [96]) produced lesions in three of sev-
en dehydrated rats. Dextropropoxyphene (100 mg/
kg/day) produced renal papillary necrosis in one of
nine rats, but six showed medullary calcification
[96].
Brown and Hardy [101] gave up to 1,300 mg/kg
phenacetin to female Sprague Dawley rats for 51
days and a similar dose of phenazone and up to 1,200
mg/kg amidopyrine for 38 days. Phenazone caused
persistent celluria with some cellular infiltration;
amidopyrine produced severe papillary necrosis but
no celluria; phenacetin caused neither effect. All
drugs impaired concentrating power in this experi-
ment.
The effects of high doses of aspirin or APC in rats
(Sprague-Dawley and Wistar) are enhanced by dehy-
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dration and oligemic shock [8, 70, 72, 97]. Arnold et
aT [102, 103], however, gave single doses of 100 mgI
kg to Wistar rats and observed transient cortical
damage; tubular regeneration commenced within 24
hours and was complete in three days, despite con-
tinuation of dosing where this was done. When
lesions were observed at 12 hr, a dose response was
seen, notably in females (100 to 600 mg/kg/day aspi-
rin). Some degree of protection from the single large
dose of aspirin was seen up to three weeks after
administration, and when 10 mg/kg was given daily
for nine days, some protection against a repeat dose
of 40 mg/kg was afforded. Arnold et al [103] report-
ed, too, that pretreatment with phenobarbitone
appeared to reduce the severity of the lesions, but no
details were given. Papillary necrosis was never seen
in these studies, and alkalization had no effect on the
cortical lesions. Lesions exclusively in the cortex of
the kidney have been observed before in patients on
salicylate therapy [103].
Ibuprofen, at doses approaching the LD50, pro-
duced dilation of the distal tubules [104]. In long
term toxicity studies in rats initially given 180 mg/kg,
but reduced to 60 mg/kg per day because of the
intestinal ulceration, no histologic damage was
detected, but data available on medullary function is
scanty [104].
Data on concentrations of aspirin in total body
distribution, plasma, and renal tissue are conflicting:
Leeling, Philipps, and Kowalski [105] found a linear
relation between aspirin dose, average renal tissue
concentration in mg/g of tissue, and plasma concen-
tration in mg/ml when using doses of aspirin of 100
mg/kg to 700 mg/kg (this last dose approached the
LD50; 3 of 21 rats died). Much lower plasma and
tissue concentrations were obtained when buffered
effervescent aspirin was used—this preparation pro-
duces an alkaline urine which lowers tubular reab-
sorption of salicylic acid and increases excretion,
which could be the basis of the findings by Nanra and
Kincaid-Smith [70], viz, that addition of bicarbonate
to a regime of plain aspirin (500 mg/kg/day) reduces
the incidence of renal papillary necrosis by one half.
Bluemle and Goldberg [1061 found that doses
between 170-300 mg/kg of aspirin or 300 mg/kg of
phenacetin or paracetamol given separately or to-
gether (170mg of aspirin plus 300mg ofphenacetin per
kg of body wt), acutely with or without hydration,
were handled differently by the kidney. At the time of
peak concentrations in the blood, cortical and medul-
lary assays were performed. No medullary gradients
for salicylate was found, whether the animals were
dehydrated or not, but free and conjugated paraceta-
mol concentration rose sharply in the inner medulla
during dehydration. The gradient was more than 10:1
for conjugated paracetamol and 19:1 for free parace-
tamol. Salicylate did not affect the paracetamol gra-
dient. The pH dependency of salicylate clearance
and distribution was not determined.
Duggin and Mudge [107, 108] have confirmed the
work of Bluemle and have overcome objections
regarding the contribution made by tubular fluid in
the medulla; they also confirm that paracetamol is
concentrated in the medulla and that dehydration
increases the gradient. Paracetamol is sparingly
bound to protein(c.f., aspirin) and is therefore filtered
by the glomerulus and reabsorbed by the tubule by
simple diffusion; this is true for its conjugates which
at low concentrates are actively secreted and at high
concentrations reabsorbed (dog). Phenacetin is not
concentrated in the medulla.
The data with regard to the medullary gradient for
aspirin is conflicting. Bluemle and Goldberg [1061
found no gradient in the dog, but Gault [1091 demon-
strated a gradient for aspirin in rabbits and guinea
pigs (1:7, rabbit; 1:3, guinea pig) and a modest gra-
dient for paracetamol (1:2.7, rabbit) and for phenace-
tin (1:3.6, rabbit). The radioactivity of the labelled
aspirin in the kidney was 20 times that of the liver,
spleen, pancreas, muscle, and brain.
Quintanilla and Kessler [110] gave sodium salicy-
late to dogs (3 mmoles/kg) and also described a med-
ullary gradient for salicylate of a factor of 1:5 to 3
(see their table 7). This, however, could be artefac-
tual, as the medullary concentration was exactly
equal to the plasma concentration, and the "gra-
dient" was due to very low concentrations in the
cortex. These workers also found that saucy late
administration induced a prompt diuresis with excess
secretion of sodium, potassium, and chloride, and
occasionally glucose, which is the reverse of the
effects found in man.
Little data is available on the kidney/blood ratio
for salicylate in patients; however, in two patients
dying of salicylate poisoning, the kidney blood ratios
were 8.0/15.0 and 82.4/0.6; such a variation makes
any conclusion impossible [106, 1101.
Whitehouse [Ill] has shown that when guinea
pigs were pretreated with aspirin at 200 mg/kg/day,
blood concentrations of a single dose of paracetamol,
(150 mg/kg) were higher; and more significantly,
excretion of paracetamol by the kidney was inhibit-
ed, although sulphation and glucuronidation were
unaffected. Comparable results have been found in
man [1121. Whitehouse believes that aspirin com-
petes preferentially for the common anionic secreto-
ry mechanism in the kidney tubule.
Finally, Carro-Ciampi [113] has shown that a 50%
reduction in posttreatment plasma concentrations of
phenacetin is obtained with the first ten days of
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repeated phenacetin treatment at a dose of 0.4 g/kgl
day in albino rats; in the guinea pig, posttreatment
phenacetin concentrations fell to only approximately
20%. Paraphenetidine levels increased as treatment
proceeded in guinea pigs, but it fell in rats.
In man it has been shown that: 1) The absorption,
excretion, and metabolism of phenacetin and aspirin
does not vary with the tubular cell response [114].
2) The recovery of phenacetin and its metabolites
is essentially the same whether patients have analge-
sic nephritis or not, but the renal excretion of con-
jugated paracetamol is reduced when nephropathy
is present, and this correllates with reductions in
the glomerular filtration rate. The metabolism of
phenacetin, in contrast to aspirin, is not pH depen-
dent [115]. 3) Steady state salicylate concentrations
are decreased when aspirin is given chronically (20
days) in healthy volunteers. The average plasma con-
centration at day 21 was approximately half that of
day 7 [116]. 4) Met-hemoglobin formation [1171 in
abusers of analgesic mixtures containing phenacetin
is significantly greater than in normal subjects or
patients with impaired renal function. The relevance
of met-hemoglobin formations to renal disease per se
is disputed, however. 5) There is evidence that the
limiting pathway on the formation and excretion of
metabolites of aspirin [118], i.e., salicyluric acid and
salicylphenolic glucuronide, does not increase pro-
portionately with dose (from 65 mg/kg to 100 mg/kg
daily).
Indomethacin plasma concentrations in man [119]
following a standard dose of 100 mg are significantly
increased when buffered aspirin is given before or
concurrently.
Van Ginneken [120] has performed the most com-
prehensive study of pharmacokinetics of commonly
used analgesics in healthy volunteers. Ibuprofen,
aclofenac, fiufenamic acid, mefenamic acid, phena-
zone and its isopropyl and methylamino derivatives,
paracetamol, phenacetin, acetylsalicylic acid, and
sodium salicylate were given as single or multiple
(ibuprofen, aclofenac, acetylsalicylic acid) doses for
7 to 14 days. Chemical methods were used for esti-
mation of plasma and urine concentrations; in addi-
tion to plasma and urine kinetics, an estimation of
protein binding and red cell uptake was made.
Ibuprofen and aclofenac had small volumes of
distribution, high protein binding, but short half-lives
(due to small volume of distribution). Ibuprofen was
excreted almost unchanged in the urine (c.f., ado-
fenac, 50%) and secreted almost unchanged by the
tubule in contrast to aclofenac. No accuminulation of
either occurred, but both showed marked fluctua-
tions in plasma concentrations following repeat
dosing.
The fenamates showed irregular plasma curves,
which could not be fitted to any simple kinetic mod-
el. The renal excretion was negligible and the biologi-
cal availability of the tested formulations was low;
although flufenamic acid was better absorbed than
mefanamic acid.
The pyrazoles showed large inter-individual varia-
tions and large volumes of distribution, and the
group showed large differences in clearance,
although as a whole, renal clearance played only a
minor role. 4-Aminophenazone is eliminated quite
differently from the others in the group; 40% is elimi-
nated partly by renal excretion (refer to the thesis
[120] for detailed discussion).
Phenacetin produced very low plasma concentra-
tions due to high hepatic clearance, in contrast to
paracetamol, and the pharmaceutical formulation of
phenacetin produced marked differences in the
absorption.
Salicylates showed the same volume of distribu-
tion as did ibuprofen and aclofenac, the plasma
kinetics were non-linear, and at higher doses clear-
ance decreased; both tubular secretion and reabsorp-
tion occurred which confirm earlier findings. The pH
dependency of excretion was once again demonstrat-
ed in chronic studies: doubling the daily dose of
sodium salicylate from 1.5 to 3 g led to a four to five-
fold increase in average plasma plateau concentra-
tion, which fits well within the model of capacity-
limited elimination.
The reader should refer directly to this excellent
monograph which shows clearly the virtue of repeat
plasma kinetics after acute and repeated dosing
[120].
Extrapolation of findings from animals to man:
Species differences. The survival of any animal spe-
cies reflects the adaption, in both form and function,
to its habitat. Animal experiments have been per-
formed mainly in rats, but also in guinea pigs, rab-
bits, cats, dogs, baboons, monkey, and pigs. All
have important structural and functional differences
in comparison to man. This is true even of animals
whose kidney architecture and physiology must
closely resemble that of man (probably the pig and
the monkey).
The rat kidney has only a single papilla, the rela-
tive length of which is greater than man's, so that the
number of long nephrons is higher than man [95,
121]. In man, the number of short looped nephrons is
86% (c.f., pig, 97%), and the papilla is better sup-
plied with blood, compared to the rat. The supply in
the rat is postglomerular only, but the edges of the
human papilla are supplied from aglomerula vessels,
first appearing in intrauterine life and becoming more
important as man ages. The central core of the papil-
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la, too, has an aglomerula supply, so the loss of
glomeruli with aging does not imperil the blood sup-
ply to such an extent. The medullary flow in man is
less well studied, but it is likely that the main meta-
bolic pathway in the medulla is the anaerobic utiliza-
tion of glucose [1171. There is a high sympathetic
innervation to the rat efferent arteriole, to the upper
parts of the vasa rectae and to the juxtamedullary
efferent arteriole which (in the rat) contain contrac-
tile cells; the sympathetic nerve supply to the human
is not well studied, however. In summary, the kidney
of the rat has major architectural differences to that
of man; the latter is, if anything, better able to with-
stand anoxia.
The strain used is a further factor. Boyd [122] has
summarized the etiologic factors affecting phenace-
tin toxicity in the rat, and seasonal variation in sus-
ceptibility has also been noted repeatedly by Kin-
caid-Smith. Male Manor Farm rats have been shown
to be much more susceptible to an indomethacin
derivative than are Charles River CD rats [94]. Wis-
tar rats have a higher incidence of natural renal
malformations which makes long-term studies diffi-
cult to interpret. The Gunn rat [123, 124] has been
particularly susceptible to the development of papil-
lary necrosis from aspirin in doses which did not
affect Wistar rats at all (200 to 500 mg/kg aspirin; 500
and 190 mg/kg/day APC). The reasons for this have
been discussed by Axelsen and Burry [125]. Sex-
related susceptibility has been shown in the case of
sudoxicam [127] (where the plasma concentration is
much higher in females), and age-related susceptibili-
ty has been shown with a derivative of indomethacin
[94, 102, 122]. In many studies, only female Wistar
rats have been used, e.g., Nanra et al [96], Saker et
al [134], and in other studies the sex is not stated.
Findings in different animal species have been
reviewed by others [94, 101, 126, 127].
As the pig has a multi-papillary kidney and the
ability to concentrate urine in a manner comparable
to man, it is of interest that the pharmacokinetics of
salicylates in pig and man are comparable. First
studies of analgesic nephropathy are appearing now
[95]. Wiseman and Reinhart [127] summarized the
situation: "renal papillary necrosis has been pro-
duced mainly in rats, occasionally in rabbits and
dogs, and rarely in monkeys," although Lechat,
Levillian, and Dechezlepaetre [52] reported that gla-
phenine causes tubular lesions in baboons. The
lesions produced by phenylbutazone and indometha-
cm in cat and dog have already been referred to.
There seems no good reason why these species
should be used in preference.
Proposed mechanisms for the genesis of the renal lesion
1) Direct toxic effect by concentration in inedul-
lary tissue. The consensus of opinion is that the first
lesion in experimental analgesic nephropathy occurs
in the long loop of Henle and vasa recta, areas where
higher concentrations of (some) compounds occur.
Maximum concentrating ability may be lost in the
absence of detectable structural damage, and there is
evidence from animal experiments that this occurs in
experimental analgesic nephropathy.
The data regarding cortico/medullary gradients for
commonly used analgesics has been summarized
earlier, and there is direct evidence that dehydration
enhances the severity of the experimental lesion
from high doses of aspirin and APC, and the medul-
lary gradients where they exist, although this does
not hold for studies when lower doses were used.
Indirect support to the direct toxic effect of analge-
sics has been provided by the elegant experiments of
Hardy [123, 124] and Brown and Hardy [101].
Although removal of the papilla in the rabbit [124]
produced severe damage per se, this was probably
due to the technique employed and the ensuing
ischemia. This can be avoided, and the partially
papillectomized kidney (rat) functions as an intact
organ. When a fenamic acid derivative is given to
such rats (known from previous experiments to pro-
duce renal papillary necrosis consistently), renal
papillary necrosis occurs only in the intact kidney
(i.e., not in the contralateral partially papillectom-
ized kidney); the cortical lesion also occurred in the
intact kidney, suggesting the papilla to be the prima-
ry site of damage. The interesting possibility arises; if
the site of concentration of analgesics is removed,
does this protect the kidney against further direct
toxic damage, while maintaining the ability to con-
centrate urine at least under conditions of mild fluid
deprivation?
In man the shedding of the normal papilla was
thought to carry a poor prognosis, but Kingsley et al
[11] stated that there is "a little evidence that it has
any permanent effect on renal function."
2) The role of anoxia. The oxygen tension in the
human kidney is known to fall from 100 mm Hg in
the cortex to about 20 mm Hg in the medulla [128],
Bernanke and Epstein [129] have shown that in the
(hydropenic) dog, the medulla receives only one-
tenth to one-twentieth of the cortical supply. The
medulla, therefore, is clearly vulnerable to ischemia
in both species.
Anoxia may result from the following changes in
the vascular tree: a) reduction in flow by vasocon-
striction or mesangial thickening, b) platelet aggre-
gates, c) occlusion of blood vessels by interstitial
hyperplasia, d) changes in the oxygen affinity of
hemoglobin, e) changes in viscosity.
Nanra et al [96, 130] have reviewed data on vascu-
Analgesic nephropa thy: Drug mechanisms 21
lar damage, and they have demonstrated that APC
(900 mg/kg/day), aspirin (500 mg/kg/day), paraceta-
mol (3,000 mg/kg/day), caffeine (150 mg/kg/day),
phenylbutazone (10 mg/kg/day), mefanamic acid (100
mg/kg/day), all lowered medullary flow, mefanamic
acid being the most active in this respect. The
ischemia produced correlated with impaired medul-
lary function, but not with the histological lesions.
This work is so important that it should be repeated
with control groups in each subset, as a number of
maneuvers (dehydration, shock, diuresis) were
employed which should be stratified.
Endothelial necrosis and vascular obliteration
have also been reported in animals [97, 1311, but not
in man. Brown et al [101] reported minor vessel
changes in rats, but Abrahams [1321 reported a spe-
cific microangiopathy in patients. Nanra and Kin-
caid-Smith [96] also reported platelet aggregates in
the vasa recta, which is parallel to the findings of
Abrahams, Rubenstein, and Levin [131] but not to
those of Arnold et a! [102] and Ham and Tangue
[133]. Saker and Kincaid-Smith [134] observed
adherent platelets, but no thrombi. In view of the
known effects of the nonsteroidal antiinflammatory
agents on platelet aggregation and adhesion, it would
seem very unlikely that they would induce aggrega-
tion or thrombosis.
Blood flow may be reduced by occlusion of vessels
by surrounding tissues. The data here is conflicting:
Gault, Blennerhasset, and Muehreke [67] confirmed
the earlier work of Clausen by showing an increase in
interstitial connective tissue with an increase in col-
lagen about the walls of the vasa recta and tubule.
These changes were observed early in the disease.
Molland observed quite the opposite—damage and
disappearance of interstitial cells [135].
Salicylate administration reduces erythrocyte 2,3-
diphosphoglyceride in a dose-related manner, which
correlates well with the plasma concentration. Such
reduction increases the affinity of hemoglobin to
oxygen, thereby depriving tissues; and Kravath,
Abel, and Colli [136] have quoted data suggesting
that salicylates increase venous oxygen saturation by
10 to 20% in rat and man.
3) Metabolic effects. The main metabolic pathway
in the inner renal medulla consists chiefly of the
anaerobic utilization of glucose. Aspirin has been
shown to inhibit the hexose monophosphate shunt in
medullary tissue [117] (unlike paracetamol). In the
isolated rat tubule [137], salicylate administration
reduced intracellular ATP [137], resulting in a
reduced rate of gluconeogenesis; however, in the
whole medulla of the dog, Quintanella and Kessler
[110] found medullary ATP to be unaffected and
comments that this is to be expected, as the metabo-
lism there is primarily glycolytic. Adenosine triphos-
phate (ATP) fell and adenosine monophosphate
(AMP) rose in the cortex, indicating that aspirin,
in this region, does uncouple oxidative phos-
phorylation.
Davidson, Daffist, and Shippey [138, 139], using
dog renal medullary slices in aerobic or anaerobic
conditions, showed that only when salicylic acid and
paracetamol were given together was substrate
metabolism altered, and that salicylic acid inhibited
amino acid incorporation into protein. Paracetamol
has little effect alone, but it enhances that of saucy-
late. This matter is discussed further in other articles
[6—8, 71, 140, 141].
4) Immunological. Little data is available. Murray
and von Stowasser [142] postulated, on the basis of
glomerular deposits and positive staining of glomer-
uli incubated with fluorescent antiserum, that there is
an immunologic basis, that the amino group con-
tained in most analgesics may be responsible, and
that these findings parallel to some extent the earlier
views of Harrow. In human studies, however, Gault
et a! [67] found no IgC or f3lC globulin in the cortex
or medulla of six patients with early analgesic
nephropathy.
5) Prostaglandins. The renal papilla is the main
source of prostaglandins in the kidney. As "aspirin-
like" drugs inhibit prostaglandin biosynthesis, could
this property be relevant to the genesis of analgesic
nephropathy? (See [143—148].)
The degree of inhibition of prostaglandin synthe-
tase by the nonsteroidal antiinflammatory drugs
depends very much on the substrate employed [144,
145]. The PG2 series are derived (by definition) from
arachidonic acid. In the rabbit medulla only a 2 to
3% conversion has been observed; in the cortex,
none. Despite this low level of metabolism in the
rabbit, however, high levels of A2, E2, and F2 in the
medulla of the rabbit have been measured and posi-
tively identified by mass spectrometry and gas chro-
matography [1491. In the rat, there is histochemical
evidence for the existence of prostaglandin hydro-
genase in the tissue surrounding the ascending loop
of Henle, and there is circumstantial evidence of
prostaglandin synthesis in the dog also.
The rank order of inhibition of synthetase in the
guinea pig lung by the nonsteroidal antiinflammatory
drugs is as follows: meclofenamic acid > niflumic
acid > mefenamic acid > flufenamic acid > naprox-
en > phenylbutazone > aspirin, or ibuprofen [144,
150, 151]. Fjalland eta! [152] would place indometh-
acm before flufenamic acid, and Ku, Wasuary, and
Cash [153] would place diclofenac as the most potent
of all. Aspirin and indomethacin inhibit synthetase in
the rabbit medulla, producing inhibition of E2 and
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F2, also. Paracetamol appears to inhibit brain syn-
thetase only.
a) Modulation of the effect of reninlangiotensin.
Angiotensin and noradrenalin increase renal perfu-
sion pressure and the basal output of prostaglandin-
like materials in the rabbit and rat; when the synthe-
sis of the latter is blocked by indomethacin, the
effects of the autonomic neurotransmitters are aug-
mented or reduced depending on the experimental
situation. When indomethacin is given intraarterially
(1 to 2pg/ml) the magnitude of duration of the
response to the pressor agents is reduced [1541. The
pressor effects of noradrenalin were enhanced when
PGE2 was infused into the kidney in amounts which
by themselves had no pressor activity, and Gagnon,
Gaulhier, and Regoli [1551 showed that when the
tissues are pretreated with indomethacin (2g/m1)
the increases in perfusion pressure induced by angio-
tensin and noradrenaline were significantly greater.
Nerve stimulation, too, releases prostaglandins,
and indomethacin can block the effects of nerve
stimulation and produce a rise in systemic blood
pressure in every case and total renal blood flow in
some experiments [1491.
Vasoconstriction per se releases prostaglandins.
Two receptors for angiotensin are proposed. One
modifies prostaglandin secretion, the other is con-
cerned solely with vasoconstriction [155].
In dogs, indomethacin reduces renal blood flow
from 15 to 45% (as does aspirin) and causes redistri-
bution from the inner to the outer cortex. Berg dis-
cusses reasons why the effects are more pronounced
in human patients with renal failure than in normal
subjects [73, 74].
b) Direct vascular effects. Although PGF2c, is
mildly pressor, it has negligible effects on renal vas-
cular resistance. PGE2 on the other hand produces
vasoconstriction in the isolated perfused kidney and
reduces renal blood flow (in contrast to the earlier
findings of Lee, quoted by Arnold [1031) Simple
inhibition of this compound, therefore, would not
explain the reduction in medullary blood flow
observed by Nanra and Kincaid-Smith [1301. Infu-
sions of arachidonic acid produces hypotension in
guinea pigs. Aspirin will inhibit this effect [156].
Pretreating animals with salicylic acid before admin-
istering aspirin, however, produces a normal
response to arachidonic acid, i.e., salicylic acid pre-
vents inhibition by aspirin.
c) Natriuresis. Short-term administrations of aspi-
rin and indomethacin produce sodium and water
retention. Donker, Arisz, and Brentjens [75] believe,
in the case of indomethacin, that this is a conse-
quence of inhibition of prostaglandin synthesis,
which in turn leads to an activation of the renin-
angiotensin system. High doses of angiotensin, how-
ever, markedly decrease rat renal tubular electrolyte
resorption, thereby inducing natriuresis. This effect
can be enhanced by indomethacin [157], i.e., urine
flow and sodium excretion increase in this
experiment.
Bartelheimer and Senft [158] also failed to show
water and sodium retention during administration of
indomethacin (8 mg/kg) in rats, although phenylbuta-
zone and oxyphenbutazone did do so. It is clear,
then, that indomethacin produces varying responses
with regard to renal blood flow and glomerular filtra-
tion rate in different species and depending on the
experimental situation.
The natriuretic effect of pro staglandins could
result from an effect on oxidative metabolism. Lee
[159] has shown that prostaglandins inhibit interme-
diary metabolism which, by inhibiting sodium and
potassium ATPase, leads to a diminution of high
energy intermediates available for sodium transport
and, thus, produces natriuresis.
The reader is referred to the papers of Berg 1173,
74], Davis and Horton [149], and Gagnon, Gaulhier,
and Regoli [155] for a fuller discussion. It is clear,
however, that the vascular changes induced by pros-
taglandins are complex and their inhibition by non-
steroidal antiinflammatory agents are comparably so.
The data in man shows acute sodium and water
retention following administration of an analgesic,
e.g. aspirin, which could be explained by an inhibi-
tion of the natriuretic effects of pro staglandins; how-
ever, during chronic administration of analgesics,
inappropriate sodium loss is present.
Summary
The situation in the experimental field is unre-
solved; too many factors require clarification before
the critical experiment can be conducted to settle the
matter once and for all. However, as there is now
plentiful evidence to convince any reasonable physi-
cian that commonly available analgesics, when
abused, carry a significant health risk, one may rea-
sonably ask whether any further experimental evi-
dence is needed?
The object of this review is in no sense divisive,
i.e., by pointing out discrepancies in the available
data to thereby cloud the issue rather than resolve
them. The problem of abuse lies properly in the field
of public health education, and the first step to this
would surely be an appropriate warning on the pack-
aging of all commonly used analgesics.
For future research, however, government health
authorities should be guided in their preclinical test-
ing requirements for mild antiinflammatory analge-
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sics, and enough is now known to draw up guidelines
for good laboratory practice in this field.
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